131 articles by Michael Gibney

• How to succeed in biotech: A serial entrepreneur’s tips for surviving tough times

  Nov. 30, 2023

• The head of AstraZeneca’s new digital health business on how the pharma is leveraging tech

  Nov. 28, 2023

• Organon’s chief medical officer wants to change how the world sees women’s health

  Nov. 22, 2023

• AstraZeneca showed the pandemic isn’t over for immunocompromised patients. What’s next?

  Nov. 16, 2023

• A biotech tackles drug discovery with transcription factor know-how

  Nov. 15, 2023

• How pharma leaders talk about ethics in a highly criticized industry

  Nov. 9, 2023

• The thorniest questions facing pharma, according to a leading bioethicist

  Nov. 6, 2023

• How Big Pharma keeps the oncology engines hot with a host of strategies

  Nov. 2, 2023

• Roivant’s $7B Roche deal was a ‘moment of opportunity,’ CEO says

  Oct. 31, 2023

• Red Jacket: Dr. Jeremy Levin, a transformational leader

  Oct. 27, 2023

• Pfizer’s new shot approval adds to a growing vaccine prowess

  Oct. 24, 2023

• Actor and epilepsy advocate Greg Grunberg wants the world to ‘talk about it’

  Oct. 19, 2023

• PharmaVoice 100s: Rare disease warriors

  Oct. 16, 2023

• Alnylam CEO, ‘disappointed’ with FDA’s Onpattro rejection, pivots to the future

  Oct. 12, 2023

• FDA’s ‘ivory tower thinking’ ignores promising biomarkers, says a rare disease CEO

  Oct. 5, 2023

• PharmaVoice 100s: Cancer care visionaries

  Oct. 2, 2023

• The PharmaVoice 100: Trailblazers

  Sept. 29, 2023

• Pfizer CEO Albert Bourla led Big Pharma bonus payouts over 5 years — but he’s no Elon Musk

  Sept. 28, 2023

• Do humans have a place in pharma’s AI future?

  Sept. 26, 2023

• As the opioid crisis seethes, a long-lasting treatment could offer new ammunition

  Sept. 21, 2023

• Moderna’s bold five-year plan reflects Big Pharma tradition of ‘Will they deliver?’

  Sept. 15, 2023

• In the renal space, innovation could tackle health disparities. But the system doesn’t reward it.

  Sept. 14, 2023

• ‘Not all rainbows and unicorns’ — a former CEO dishes on his rocky biotech ride

  Sept. 7, 2023

• Finding the right flu vaccine is hard. Getting people to take it is harder.

  Aug. 30, 2023

• ‘We need to do better:’ A biotech CEO on standing apart from the crowd

  Aug. 29, 2023

• ‘Eris’ and other new COVID strains accelerate vaccine push from Pfizer, Moderna, Novavax

  Aug. 24, 2023

• Henrietta Lacks’ immortal cells put biopharma profits under a microscope

  Aug. 23, 2023

• How an AstraZeneca exec is leading the charge in the next immuno-oncology era

  Aug. 17, 2023

• Biogen’s Reata acquisition reflects biopharma’s inevitable M&A, IPO return to growth

  Aug. 10, 2023

• In the era of blockbuster obesity drugs, a personalized approach could boost outcomes

  Aug. 8, 2023

• New Alzheimer’s treatments are the tip of the iceberg in a long-stymied area of medicine

  Aug. 3, 2023

• How CymaBay overcame a NASH failure for another shot at liver disease success

  Aug. 2, 2023

• Big Pharma CEOs get candid about pricing and M&A

  July 28, 2023

• For Merck, understanding maternal mortality is the first step toward equity

  July 25, 2023

• Google for genes? This AI company aims to curate the entire human genome.

  July 20, 2023

• As biologics boom, here’s how manufacturers are keeping up

  July 19, 2023

• Novo’s workhorse Ozempic could shine in new areas

  July 13, 2023

• Merck’s New Jersey campus is getting a biotech makeover

  July 11, 2023

• Following FDA’s full approval of Leqembi, here’s what else is in the Alzheimer’s pipeline

  July 7, 2023

• A pharma summer — how leaders unwind and recharge their teams in the warmer months

  June 30, 2023

• Intercept’s NASH retreat is the latest setback for a challenging liver disease

  June 27, 2023

• DIA’s chief exec is on a mission to grow its footprint across healthcare

  June 22, 2023

• AI has secured a footing in drug discovery. Where does it go from here?

  June 20, 2023

• The ingredients of a successful biopharma collaboration

  June 13, 2023

• Yes, biopharma still has a reputation problem. These leaders are looking for solutions.

  June 8, 2023

• Janssen and Legend’s longtime collaboration lands a CAR-T win at ASCO

  June 5, 2023

• How Takeda finds the hottest new science to fuel its oncology work

  June 1, 2023

• From FTC to SCOTUS, Amgen’s woes are potential ‘game changers’ for the industry

  May 25, 2023

• The power of genetics — how research into gene sequencing could revolutionize biopharma

  May 23, 2023

• Led by the Pfizer-Seagen deal, ADCs are starting to ‘take center stage’

  May 9, 2023

• A biopharma CEO opens up about executive salaries — and why he wants to change the status quo

  May 4, 2023

• From science to strategy, this exec is painting Genmab’s bigger picture into the next decade

  May 2, 2023

• How biopharma dealmaking kicked back into action

  April 27, 2023

• Pharma’s immunology field is full of blockbusters, and it’s just getting started

  April 27, 2023

• Cure Ventures has $350M to pour deep into biotech ‘company building’

  April 20, 2023

• Depression has long been treated chronically — Sage wants to change that

  April 18, 2023

• Fighting vaccine hesitancy may require a new approach from pharma

  April 13, 2023

• Despite J&J’s exit, Big Pharma is closing in on a launch of the first RSV vax this year

  April 6, 2023

• The silver linings in biotech’s wobbly market

  April 4, 2023

• Digital biomarkers lay the groundwork for precision medicine beyond the bloodwork

  March 30, 2023

• SCOTUS to decide ‘fundamental change’ in biologics patents with fate of Amgen v. Sanofi

  March 28, 2023

• This GSK clinical data leader embraces the ‘Rubik’s cube’ problem: solving for all sides at once

  March 23, 2023

• SVB’s collapse had limited impact on biopharmas — but a broader financial crisis could change the landscape

  March 21, 2023

• Return of the megadeal: Pfizer’s Seagen buy has the industry asking if super-sized M&A is back

  March 16, 2023

• A rising oncology powerhouse in China, BeiGene looks to strengthen its international punch

  March 14, 2023

• Janssen neuroscience leader takes on rare diseases one small ‘eureka’ at a time

  March 9, 2023

• Eli Lilly took price cuts into its own hands. Will other pharmas follow suit?

  March 7, 2023

• The ‘recovering academic’ leading Allogene to the next stage of cell therapy

  March 2, 2023

• Why the pharma industry is digging deep in rare disease

  Feb. 21, 2023

• Nectin’s Keytruda combo could fill gaps in immuno-oncology’s treatment paradigm

  Feb. 16, 2023

• The post-COVID outlook for decentralized clinical trials

  Feb. 14, 2023

• Leaps in vax tech — researchers find new ways to tackle old problems like fungal infections and cancer

  Feb. 7, 2023

• Execs at Pfizer, Novartis, Amgen and GSK tackle shifting priorities — reflecting the state of Big Pharma

  Feb. 2, 2023

• This biotech CEO secured two billion-dollar Big Pharma deals during the pandemic

  Jan. 31, 2023

• Economic crisis? J&J execs say that won’t stop them from hitting $60B target

  Jan. 25, 2023

• AstraZeneca’s newest asthma launch fills a gap as generics chip away at respiratory flagships

  Jan. 24, 2023

• A Moderna tie-up ushers in new era for CytomX

  Jan. 18, 2023

• Biopharma M&A may get the push it needs in 2023, but with a face lift

  Jan. 12, 2023

• Chinook Therapeutics nears the finish line in kidney disease

  Jan. 10, 2023

• Lilly, Biogen, Eisai brace for Alzheimer’s boom or bust in 2023

  Jan. 5, 2023

• Beer, dolphins and more discoveries that could shed light on Alzheimer’s disease

  Dec. 22, 2022

• Blood cancer cures aren’t here yet — but incremental combinations bring the field closer

  Dec. 19, 2022

• At the heart of hematology breakthroughs, a community of researchers and patients comes together

  Dec. 13, 2022

• For Duchenne-focused Sarepta, gene therapy is the natural next step

  Dec. 8, 2022

• 5 final FDA action dates to watch this year

  Dec. 1, 2022

• Evommune’s unique method of drug discovery is more than skin deep

  Nov. 29, 2022

• Why the biopharma ‘IPO playbook’ changed in 2022

  Nov. 21, 2022

• Is AI just hype or a real revolution in pharma? It’s complicated

  Nov. 17, 2022

• To explore cancer’s genetic mysteries, researchers turn to ‘MACHETE’

  Nov. 16, 2022

• 3 ways pharma can weather a recession

  Nov. 10, 2022

• While CAR-T wait times remain ‘heartbreaking,’ researchers push for innovations that could help

  Nov. 8, 2022

• ‘Zombie’ cells, Shkreli and cats — new research in toxoplasmosis and how the three are connected

  Nov. 3, 2022

• While DCTs get all the hype, some industry insiders say the future is a digital hybrid

  Nov. 1, 2022

• Riches, rags, riches: Is Biogen the Cinderella of biotechs?

  Oct. 27, 2022

• Biosimilars will gain ground in 2023 with Humira launches — and that’s just the beginning

  Oct. 24, 2022

• J&J reveals just how much economic turbulence is affecting Big Pharma

  Oct. 20, 2022

• He helped discover BMS’s psoriasis pill Sotyktu. Here’s what he has to say about early science in Big Pharma

  Oct. 17, 2022

• The digital therapeutics revolution is happening and Big Pharma is buying in — with caution

  Oct. 10, 2022

• Keytruda is the gift that keeps on giving for Merck, and here’s what’s next for the cancer juggernaut

  Oct. 3, 2022

• How do Biogen-Eisai’s two Alzheimer’s drugs stack up?

  Sept. 30, 2022

• From the ‘go-go days’ to a bubble crunch — the biotech sector faces its next challenge

  Sept. 12, 2022

• Entrepreneurs: Armon Sharei

  Sept. 6, 2022

• Entrepreneurs: David Katz

  Sept. 6, 2022

• Disrupters: Julie Kim

  Sept. 6, 2022

• Entrepreneurs: Kuldeep Singh Rajput

  Sept. 6, 2022

• Disrupters: Sally Allain

  Sept. 6, 2022

• First 90 Days: Adaptive Biotech’s Tycho Peterson

  Sept. 1, 2022

• The ‘long COVID’ nightmare: Data-driven alliance offers understanding of the lasting viral impact

  Aug. 29, 2022

• Patents, pandemics and pricing: a peek at the top drug from every big pharma

  Aug. 22, 2022

• Despite AbbVie’s Botox prowess, underdog Galderma has leveraged soft skills to succeed in aesthetics

  Aug. 11, 2022

• As pharma M&A ramps up, U.S. execs are bullish on more deals

  Aug. 11, 2022

• Generic subscription services like Mark Cuban’s promise cheaper drugs — but will it work?

  Aug. 4, 2022

• What’s next for Biogen? Here’s what executives are saying

  July 27, 2022

• A 'total waste'? Drug developers worry if two decades of Alzheimer's research were pointed at the wrong targets

  July 25, 2022

• With big changes ahead for J&J and Novartis, here's what the companies' execs are talking about

  July 21, 2022

• Biotech R&D spending has skyrocketed, and so have opportunities for savings

  July 19, 2022

• Why a 'fundamental shift' in regulatory submissions is on the way

  July 11, 2022

• The scientist's struggle: Lessons from the journey of mRNA pioneers Katalin Karikó and Drew Weissman

  June 29, 2022

• #DIA2022: How the industry's top regulator views the future of healthcare

  June 21, 2022

• First 90 Days: Editas Medicine’s Gilmore O’Neill

  June 13, 2022

• As cancer innovations thrive, patient access is the next piece of the puzzle

  June 8, 2022

• How to build a cancer pipeline: Big Pharma oncology heads on driving science forward

  June 6, 2022

• PBMs under fire for drug prices defend their worth

  May 26, 2022

• Pharmas can be 'more than medicine' by focusing on preventative care

  May 24, 2022

• Biotech Spotlight: Graphite Bio seeks sickle cell cure with a next-gen approach

  May 17, 2022

• With the shine of amyloid fading, tau is a rising star in Alzheimer's

  May 11, 2022

• Ultra-sensitive tests bring biomarkers into the drug development forefront

  May 5, 2022

• The 'innovation gap' haunts Big Pharma, and the race is on for the next blockbusters

  April 28, 2022

• Mouse vs. machine: Using AI to solve the animal testing model in pharma

  April 26, 2022

• A pharma mystery: Cancer-causing impurities drive joint search for answers

  April 19, 2022

• Why the war in Ukraine could accelerate the deglobalization of clinical trials

  April 12, 2022